From DCAT Value Chain Insights (VCI)
Valeant Pharmaceuticals International has appointed Paul Herendeen as executive vice president, finance and will take over the role of chief financial officer from Robert Rosiello, effective immediately.
Mr. Herendeen has more than 30 years of broad financial experience and leadership, including 16 years as CFO of Warner Chilcott and MedPointe. He joins Valeant from Zoetis, where he served as executive vice president and CFO for the past two years. As Valeant CFO, he will oversee all of the company's finance functions, including controllership, tax, and treasury. He will report directly to chief executive officer, Joseph Papa.
Mr. Rosiello will remain at Valeant as executive vice president, corporate development and strategy. He will also continue as an executive committee member, reporting directly to Mr. Papa.
Source: Valeant Pharmaceuticals
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription